94.15
price down icon2.56%   -2.47
after-market 시간 외 거래: 94.15
loading
전일 마감가:
$96.62
열려 있는:
$96.78
하루 거래량:
653.05K
Relative Volume:
1.07
시가총액:
$5.90B
수익:
$434.41M
순이익/손실:
$-128.05M
주가수익비율:
-10.24
EPS:
-9.19
순현금흐름:
$-250.52M
1주 성능:
+6.16%
1개월 성능:
+8.88%
6개월 성능:
-8.33%
1년 성능:
+40.50%
1일 변동 폭
Value
$94.11
$98.34
1주일 범위
Value
$88.05
$98.34
52주 변동 폭
Value
$66.61
$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name
명칭
Blueprint Medicines Corp
Name
전화
617-374-7580
Name
주소
45 SIDNEY STREET, CAMBRIDGE, MA
Name
직원
655
Name
트위터
@BlueprintMeds
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
BPMC's Discussions on Twitter

BPMC을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
BPMC 94.15 5.90B 434.41M -128.05M -250.52M -9.19
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-10-27 업그레이드 Oppenheimer Perform → Outperform
2023-08-21 재확인 Needham Buy
2023-07-31 업그레이드 Wells Fargo Equal Weight → Overweight
2023-06-05 다운그레이드 SVB Securities Market Perform → Underperform
2023-01-03 업그레이드 Wells Fargo Underweight → Equal Weight
2022-12-14 개시 Needham Buy
2022-11-02 다운그레이드 Oppenheimer Outperform → Perform
2022-09-14 개시 Berenberg Buy
2022-07-08 개시 Oppenheimer Outperform
2022-06-27 개시 Wells Fargo Underweight
2022-06-10 다운그레이드 Citigroup Neutral → Sell
2022-06-01 업그레이드 Jefferies Hold → Buy
2022-03-01 개시 Citigroup Neutral
2022-02-17 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-01-25 업그레이드 Stifel Hold → Buy
2021-11-19 재개 Morgan Stanley Equal-Weight
2021-09-30 재개 Stifel Hold
2021-06-04 재개 Robert W. Baird Outperform
2021-03-31 개시 Credit Suisse Neutral
2020-12-03 개시 Stifel Hold
2020-11-02 재확인 H.C. Wainwright Buy
2020-11-02 다운그레이드 Jefferies Buy → Hold
2020-10-30 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-07-15 재확인 H.C. Wainwright Buy
2020-05-05 개시 Barclays Equal Weight
2020-03-17 업그레이드 BMO Capital Markets Market Perform → Outperform
2020-01-28 개시 BMO Capital Markets Market Perform
2020-01-27 개시 BMO Capital Markets Market Perform
2019-11-06 업그레이드 Raymond James Outperform → Strong Buy
2019-10-22 개시 JMP Securities Mkt Outperform
2019-10-03 개시 H.C. Wainwright Buy
2019-09-12 업그레이드 Raymond James Mkt Perform → Outperform
2019-08-29 개시 Piper Jaffray Neutral
2019-08-15 재개 Raymond James Mkt Perform
2019-07-18 개시 Deutsche Bank Buy
2019-05-23 재개 Goldman Buy
2019-04-03 개시 Morgan Stanley Overweight
2018-09-25 개시 Leerink Partners Outperform
2017-12-11 재확인 Goldman Buy
모두보기

Blueprint Medicines Corp 주식(BPMC)의 최신 뉴스

pulisher
Nov 22, 2024

Blueprint Medicines director Coats sells $1.87 million in stock - Investing.com

Nov 22, 2024
pulisher
Nov 22, 2024

Blueprint Medicines director Coats sells $1.87 million in stock By Investing.com - Investing.com UK

Nov 22, 2024
pulisher
Nov 21, 2024

What is Zacks Research's Forecast for BPMC FY2024 Earnings? - MarketBeat

Nov 21, 2024
pulisher
Nov 21, 2024

Segall Bryant & Hamill LLC Buys 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Blueprint Medicines initiated with an Overweight at JPMorgan - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Cut by Victory Capital Management Inc. - MarketBeat

Nov 20, 2024
pulisher
Nov 18, 2024

JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024
pulisher
Nov 17, 2024

Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN

Nov 15, 2024
pulisher
Nov 14, 2024

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Mastocytosis Treatment Market Forecasted for Major Expansion - openPR

Nov 14, 2024
pulisher
Nov 14, 2024

Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 14, 2024
pulisher
Nov 09, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat

Nov 08, 2024
pulisher
Nov 05, 2024

Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online

Nov 05, 2024
pulisher
Nov 04, 2024

Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve

Nov 04, 2024
pulisher
Nov 04, 2024

Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance

Nov 02, 2024
pulisher
Nov 01, 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa

Oct 31, 2024
pulisher
Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com Australia

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire

Oct 30, 2024
pulisher
Oct 28, 2024

When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St

Oct 28, 2024
pulisher
Oct 28, 2024

Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Oct 28, 2024

Blueprint Medicines Corp (BPMC) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):